Press release
Dengue Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight
Dengue Clinical Trials
Explore our latest breakthroughs in Dengue Research. Learn more about our innovative pipeline today! @ Dengue Pipeline Outlook - https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Dengue Pipeline Report
• In June 2025, Takeda announced results of a Post-vaccination Surveillance for Monitoring the Adverse Events Following Immunisation With QDENGA in a Real-world Setting in Malaysia (PRIME-Q)
• In May 2025, Novartis announced results of a Randomized, Participant- and Investigator-blinded, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever
• In March 2025, AbViro LLC announced a phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Safety and Efficacy of 3 Dose Levels of AV-1 in Healthy Adults Challenged With a Controlled Human Infection Strain of DENV-3.
• In March 2025, Takeda organized a study is to learn about TDV's ability to create an immune response in adults, adolescents, and children administered. In this study, participants will receive 2 vaccinations with TDV (the second 3 months after the first). During the study, participants will visit their study clinic 5 times.
• In March 2025, Novartis Pharmaceuticals announced a study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.
• DelveInsight's Dengue pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Dengue treatment.
• The leading Dengue Companies such as Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
• Promising Dengue Therapies such as EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.
Stay informed about the cutting-edge advancements in Dengue Treatments. Download for updates and be a part of the revolution in infectious disease care @ Dengue Clinical Trials Assessment - https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dengue Emerging Drugs Profile
• VIS 513: Visterra
VIS513, is a monoclonal antibody in development for the treatment of Dengue, a serious mosquito-borne virus, which in its most severe forms is characterized by uncontrolled bleeding leading to organ failure and death. VIS513 has in vitro and in vivo activity against all four Dengue virus serotypes found globally.
• TAK-003: Takeda
Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic "backbone" for all four vaccine viruses. Clinical Phase II data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes, in both seropositive and seronegative participants, which persisted through 48 months after vaccination, and the vaccine was found to be generally safe and well tolerated.
• CDX DENV: Codagenix
Codagenix has leveraged the platform to re-design contemporary strains of dengue and demonstrate a balanced tetravalent vaccine that is safe and immunogenic in primates. CDX DENV, is a Synthetic vaccine being developed in the Pre-Clinical stage for the treatment of Dengue.
• AT 752: Atea Pharmaceuticals
AT-752, a diastomer of AT-527, is a novel purine nucleotide prodrug, designed to treat patients either newly infected or previously infected with the dengue virus. AT-752 has an favorable preclinical safety profile and has demonstrated potent in vitro activity against all dengue serotypes tested as well as potent antiviral activity in predictive animal models. Atea Pharmaceuticals plan to conduct clinical studies that will evaluate the daily administration of AT-752 over a short period of treatment, in order to negate the progression of infection and reduce the occurrence of life-threatening conditions associated with severe dengue.
The Dengue Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Dengue with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dengue Treatment.
• Dengue Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dengue Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dengue market
Learn more about Dengue Drugs opportunities in our groundbreaking ALDengue Research and development projects @ Dengue Unmet Needs - https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Dengue Companies
Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals and others.
Dengue pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Dengue Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Discover the latest advancements in Dengue Treatment by visiting our website. Stay informed about how we're transforming the future of infectious disease @ Dengue Market Drivers and Barriers, and Future Perspectives - https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Dengue Pipeline Report
• Coverage- Global
• Dengue Companies- Visterra, Takeda, Codagenix, Atea Pharmaceuticals, Abivax, Janssen Research & Development, Plex Pharmaceuticals, and others.
• Dengue Therapies- EYU688, V181, Butantan-DV, JNJ-64281802, Tetravalent Dengue Vaccine (TDV), and others.
• Dengue Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dengue Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Dengue Pipeline on our website @ Dengue Drugs and Companies - https://www.delveinsight.com/sample-request/dengue-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Dengue: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dengue- DelveInsight's Analytical Perspective
7. Late Stage Products (Pre-Registration)
8. TAK-003: Takeda
9. Drug profiles in the detailed report.....
10. Mid Stage Products (Phase II)
11. Drug Name: Company Name
12. Drug profiles in the detailed report.....
13. Early Stage Products (Phase I)
14. AT 752: Atea Pharmaceuticals
15. Drug profiles in the detailed report.....
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report.....
19. Inactive Products
20. Dengue Key Companies
21. Dengue Key Products
22. Dengue- Unmet Needs
23. Dengue- Market Drivers and Barriers
24. Dengue- Future Perspectives and Conclusion
25. Dengue Analyst Views
26. Dengue Key Companies
27. Appendix
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Dengue Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight here
News-ID: 4096749 • Views: …
More Releases from DelveInsight Business Research
Narcolepsy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Narcolepsy pipeline constitutes 10+ key companies continuously working towards developing 12+ Narcolepsy treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Narcolepsy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed…
Juvenile Rheumatoid Arthritis Pipeline 2025: FDA Updates, Therapy Innovations, a …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Juvenile Rheumatoid Arthritis pipeline constitutes 8+ key companies continuously working towards developing 10+ Juvenile Rheumatoid Arthritis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Juvenile Rheumatoid Arthritis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Juvenile Rheumatoid…
Hemochromatosis Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hemochromatosis pipeline constitutes 3+ key companies continuously working towards developing 3+ Hemochromatosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Hemochromatosis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Hemochromatosis Market.
The Hemochromatosis Pipeline report embraces in-depth…
Gastroparesis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evalua …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Gastroparesis pipeline constitutes 8+ key companies continuously working towards developing 10+ Gastroparesis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Gastroparesis Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gastroparesis Market.
The Gastroparesis Pipeline report embraces in-depth…
More Releases for Dengue
Key Trend Reshaping the Dengue Treatment Market in 2025: Innovative Drug Deliver …
Which drivers are expected to have the greatest impact on the over the dengue treatment market's growth?
The escalation in cases of dengue is projected to stimulate the expansion of the market for dengue treatments. Dengue is a viral infection transmitted by mosquito bites, causing symptoms akin to the flu and can escalate to intense complications if not treated. The escalation is primarily due to progressing urbanization, climate alterations favourable to…
Key Dengue Vaccine Market Trend for 2025-2034: Advancements In Dengue Tetravalen …
What Is the Future Outlook for the Dengue Vaccine Market's Size and Growth Rate?
In the past few years, the dengue vaccine market has experienced significant growth. From $0.64 billion in 2024, it is projected to reach $0.72 billion in 2025, marking a compound annual growth rate (CAGR) of 12.4%. This notable expansion during the historical period can be credited to factors such as an increase in travel and urbanization trends,…
Dengue Vaccine Market : An Detailed Overview
Introduction:
Dengue fever is a mosquito-borne viral infection caused by the dengue virus, transmitted primarily through Aedes aegypti and Aedes albopictus mosquitoes. Affecting millions globally each year, dengue has become a significant public health concern, especially in tropical and subtropical regions. The development of dengue vaccines represents a groundbreaking advancement in preventing the disease, reducing its associated healthcare costs, and controlling outbreaks. With increasing awareness and investments in immunization programs, the…
Dengue Vaccine Market : An Overview
Introduction:
Dengue fever is a mosquito-borne viral infection that has become a significant public health challenge in tropical and subtropical regions. The disease is caused by the dengue virus, which is transmitted primarily by Aedes aegypti mosquitoes. With approximately 390 million infections annually, dengue fever places a substantial burden on healthcare systems and economies worldwide. Efforts to mitigate this burden have led to the development of dengue vaccines, designed to prevent…
"Rising Incidence of Dengue Fever Propels Dengue Virus Diagnostic Tests Market T …
According to WHO, dengue affects about 50-100 million people worldwide, annually. It is a vector-borne highly communicable disease. This report discusses the diagnostic tests used to confirm the presence of dengue in one individual.
It is true that the growth of the global dengue virus diagnostic tests market is primarily driven by an increase in the incidence of dengue fever, which is a mosquito-borne viral infection that can cause severe flu-like…
Dengue Vaccines Market 2021 | Detailed Report
Dengue Vaccines Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027.
Get Free Sample PDF (including full TOC, Tables and Figures) of Dengue Vaccines Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=4644240
The report provides a comprehensive analysis of company profiles listed below:
- Sanofi
- Takeda
Dengue Vaccines Market Segment by…
